Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,529
  • Shares Outstanding, K 70,925
  • Annual Sales, $ 31,250 K
  • Annual Income, $ -88,480 K
  • 60-Month Beta 0.22
  • Price/Sales 2.75
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade ACRS with:

Options Overview Details

View History
  • Implied Volatility 115.45% ( -13.15%)
  • Historical Volatility 68.33%
  • IV Percentile 53%
  • IV Rank 18.38%
  • IV High 494.95% on 10/26/23
  • IV Low 29.98% on 03/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 31
  • Volume Avg (30-Day) 163
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 6,650
  • Open Int (30-Day) 5,271

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.08
  • Low Estimate -0.35
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +9.82%
on 03/20/24
1.3200 -6.82%
on 04/01/24
+0.0600 (+5.13%)
since 03/15/24
3-Month
1.0500 +17.14%
on 02/07/24
1.5100 -18.54%
on 03/06/24
+0.0500 (+4.24%)
since 01/17/24
52-Week
0.5902 +108.40%
on 11/13/23
11.1200 -88.94%
on 07/17/23
-8.3400 (-87.15%)
since 04/17/23

Most Recent Stories

More News
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 21.02 (-0.05%)
ONCY : 1.0400 (-3.70%)
ONC.TO : 1.44 (-2.04%)
NVS : 93.08 (-0.13%)
IBRX : 5.24 (+6.50%)
ACRS : 1.2300 (+0.82%)
NUVB : 2.69 (-4.27%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 2.51 (-2.34%)
ONCY : 1.0400 (-3.70%)
ONC.TO : 1.44 (-2.04%)
NVS : 93.08 (-0.13%)
IBRX : 5.24 (+6.50%)
ACRS : 1.2300 (+0.82%)
NUVB : 2.69 (-4.27%)
Aclaris: Q4 Earnings Snapshot

Aclaris: Q4 Earnings Snapshot

ACRS : 1.2300 (+0.82%)
Aclaris: Q3 Earnings Snapshot

Aclaris: Q3 Earnings Snapshot

ACRS : 1.2300 (+0.82%)
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

A bull on the company became more positive on its prospects.

SF : 74.41 (+0.08%)
ACRS : 1.2300 (+0.82%)
Aclaris: Q2 Earnings Snapshot

Aclaris: Q2 Earnings Snapshot

ACRS : 1.2300 (+0.82%)
2 Low-Priced Stocks That Could Make You Richer

These two low-priced healthcare stocks could skyrocket within the next 12 months.

GILD : 66.93 (-0.56%)
INCY : 52.72 (-0.94%)
VKTX : 66.47 (-2.18%)
AXSM : 69.71 (+1.31%)
MRK : 125.37 (+0.25%)
BMY : 47.84 (-0.87%)
AGEN : 5.40 (-14.29%)
ACRS : 1.2300 (+0.82%)
Why Aclaris Therapeutics Topped the Market on Tuesday

Investors were cheered by the latest laboratory news from the company.

ACRS : 1.2300 (+0.82%)
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 4.55% and 36.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 1.2300 (+0.82%)
ACRX : 0.8600 (+7.50%)
Aclaris: Q1 Earnings Snapshot

Aclaris: Q1 Earnings Snapshot

ACRS : 1.2300 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 1.2853
2nd Resistance Point 1.2677
1st Resistance Point 1.2488
Last Price 1.2300
1st Support Level 1.2123
2nd Support Level 1.1947
3rd Support Level 1.1758

See More

52-Week High 11.1200
Fibonacci 61.8% 7.0976
Fibonacci 50% 5.8551
Fibonacci 38.2% 4.6126
Last Price 1.2300
52-Week Low 0.5902

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar